Organogenesis ‘commends’ final local coverage determinations
Organogenesis (ORGO) commends the decision by the U.S. Centers for Medicare & Medicaid Services on local coverage determination based on peer-reviewed and evidence-based data of clinical efficacy. The LCD covers skin substitute grafts/cellular and tissue-based products for the treatment of diabetic foot ulcers and venous leg ulcers in the Medicare population and is now set to become effective on February 12, 2025. Organogenesis offers 4 products for DFUs, including NuShield, and 2 for VLUs.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ORGO:
TipRanks is the most comprehensive data set of sell side analysts and hedge fund managers. TipRanks' multi-award winning platform ranks financial experts based on measured performance and the accuracy of their predictions so investors know who to trust when making investment decisions.